Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D002055 | Burnout, Professional NIH | 0.33 |
| D000077062 | Burnout, Psychological NIH | 0.24 |
| D003863 | Depression, NIH | 0.11 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The study aims to investigate the effects of Cognitive Behavioural therapy intervention on sleep and it's effects on well-being, dietary intake and food preferences during COVID-19. The study will investigate whether delivery of a CBT intervention will lead to an improvement in sleep quality and sleep duration and will consequently improve metabolic health. The participants will be randomized into two groups with one half in the intervention arm and the other in the control arm of the study.
Description: Change in accelerometer measured total sleep time
Measure: Sleep Duration Time: 0-12 weeksDescription: Changes in Accelerometer measured sleep efficiency
Measure: Sleep Efficiency Time: 0-12 weeksDescription: Changes in Accelerometer measured sleep latency
Measure: Sleep Latency Time: 0-12 weeksDescription: Changes in Accelerometer measured Total sleep Time
Measure: Total Sleep Time Time: 0-12 weeksDescription: Changes in Accelerometer measured Total time in bed
Measure: Total Time in Bed Time: 0-12 weeksDescription: Changes in Accelerometer measured Wake after sleep onset
Measure: Wake After Sleep Onset Time: 0-12 weeksDescription: Changes in subjective sleep quality measured by The Pittsburgh Sleep Quality Index
Measure: Subjective Sleep Quality Time: 0-12 weeksDescription: Changes in sleep disturbances measured by The Pittsburgh Sleep Quality Index
Measure: Sleep Disturbances Time: 0-12 weeksDescription: Changes in use of sleeping medication measured by The Pittsburgh Sleep Quality Index
Measure: Use of Sleeping Medication Time: 0-12 weeksDescription: Changes in daytime dysfunction measured by The Pittsburgh Sleep Quality Index
Measure: Daytime Dysfunction Time: 0-12 weeksDescription: Changes in habitual sleep efficiency measured by The Pittsburgh Sleep Quality Index
Measure: Habitual Sleep Efficiency Time: 0-12 weeksDescription: Changes in sleep duration measured by The Pittsburgh Sleep Quality Index
Measure: Sleep Duration (self-reported) Time: 0-12 weeksDescription: Changes in excessive daytime sleepiness measured by the Epworth Sleepiness Scale Scale range: Would never nod off 0 Slight chance of nodding off 1 Moderate chance of nodding off 2 High chance of nodding off 3 Scoring Interpretation: Minumum score is 0 and maximum score is 24. 0-5 - Lower Normal Daytime Sleepiness 6-10 - Higher Normal Daytime Sleepiness 11-12 - Mild Excessive Daytime Sleepiness 13-15 - Moderate Excessive Daytime Sleepiness 16-24 - Severe Excessive Daytime Sleepiness
Measure: Excessive Daytime Sleepiness Time: 0-12 weeksDescription: Changes in cognitive, affective and social dimensions of mental health measured by the Warwick-Edinburgh Mental Well-being Scale Scale range: None of the time 1 Rarely 2 Some of the time 3 Often 4 All of the time 5 Scoring Interpretation: The minimum score is 14 and maximum score is 70. The higher the scores indicate a greater positive mental wellbeing.
Measure: Mental Well-being Time: 0-12 weeksDescription: Changes in depressive symptoms measured by the Patient Health Questionnaire-9 Scale range: Not at all 0 Several days 1 More than half the days 2 Nearly every day 3 Scoring Interpretation: The minimum score is 0 and maximum score is 20. 0-5 - mild 6-10 - moderate 11-15 - moderately severe 16-20 - severe depression
Measure: Depression Time: 0-12 weeksDescription: Changes in anxiety measured by the Generalized Anxiety Disorder-7 Scale range: Not at all 0 Several days 1 More than half the days 2 Nearly every day 3 Scoring Interpretation: The minimum score is 0 and maximum score is 21. 0-5 mild 6-10 moderate 11-15 moderately severe anxiety 15-21 severe anxiety.
Measure: Anxiety Time: 0-12 weeksDescription: Changes in explicit liking and explicit wanting measured by the Leeds Food Preference Questionnaire Scale range: The computerized asessment includes a 100mm visual analogue scale and at the end of the response item participants will be asked: "How much do you want some of this food now? Scoring: The minimum score for VAS scale is 0 and maximum is 100. Scores are recorded and converted in to mean scores for high fat, low fat, sweet or savoury food types and different fat-taste combinations.
Measure: Food preference Time: 0-12 weeksDescription: Changes in implicit wanting and food choice measured by the Leeds Food Preference Questionnaire Scale range: The computerized asessment where participants are presented with two images and they choose which they like. Scoring: Reaction time for each answer is recorded and converted in to mean scores for high fat, low fat, sweet or savoury food types and different fat-taste combinations.
Measure: Food reward Time: 0-12 weeksDescription: Changes in craving control, craving for sweet, craving for savoury and positive mood measured by the Control of Eating Questionnaire Scale range: The asessment includes a 20 items with a 10 point scale ranging from "not at all" to "extremely" and 1 item with free text answer. Scoring: The minimum score for VAS scale is 0 and maximum is 100. The sum of items were calculated and divide by number of items in the subscale. Higher the score indicates higher cravings. Positive mood subscales and Craving Control subscales the scores were reversed, so great score indicated greater level of positve mood and craving control.
Measure: Food cravings Time: 0-12 weeksDescription: Changes in 24 hour food recall measured by the Myfood24 food diary
Measure: Dietary Intake Time: 0-12 weeksDescription: Changes in self reported weight
Measure: Anthropometric Measures Time: 0-12 weeksDescription: Changes in self reported BMI
Measure: Anthropometric measures Time: 0-12 weeksDescription: Participant feedback and information provided through interviews
Measure: Participant Interviews Time: 0-12 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports